Stimgenics Open-Label, Post Market Study
Status: | Recruiting |
---|---|
Conditions: | Back Pain, Back Pain |
Therapuetic Areas: | Musculoskeletal |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 8/1/2018 |
Start Date: | June 26, 2018 |
End Date: | January 2020 |
Contact: | David L Cedeno, PhD |
Email: | mailto:clinicalSG@stimgenics.com |
Phone: | 309-662-4321 |
Stimgenics Open-Label, Post Market Study: A Clinical Trial to Study the Effects of Stimgenics Spinal Cord Stimulation (SGX-SCS) Programs in Treating Intractable Chronic Back Pain
The purpose of this investigational study is to study the effects of Stimgenics Spinal Cord
Stimulation (SGX-SCS) in subjects with chronic, intractable pain of the trunk with lower limb
pain, including unilateral or bilateral pain associated with the following conditions: failed
back surgery syndrome, intractable low back pain and leg pain.
Stimulation (SGX-SCS) in subjects with chronic, intractable pain of the trunk with lower limb
pain, including unilateral or bilateral pain associated with the following conditions: failed
back surgery syndrome, intractable low back pain and leg pain.
This is an open-label prospective, randomized, controlled, multi-center study comparing
Stimgenics Spinal Cord Stimulation (SGX-SCS) programming approach to Standard SCS programming
approach.
Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two
study treatment groups:
- Test treatment group with SGX-SCS programming approach
- Control treatment group with Standard SCS programming approach
Data at follow-up visits will be compared between the two treatment groups, and in reference
to baseline assessments collected at the beginning of the study.
Stimgenics Spinal Cord Stimulation (SGX-SCS) programming approach to Standard SCS programming
approach.
Subjects meeting study entrance criteria will be randomized in a 1:1 ratio to one of two
study treatment groups:
- Test treatment group with SGX-SCS programming approach
- Control treatment group with Standard SCS programming approach
Data at follow-up visits will be compared between the two treatment groups, and in reference
to baseline assessments collected at the beginning of the study.
Inclusion Criteria:
1. Be a candidate for SCS system (trial and implant) per labeled indication (back and leg
pain)
2. Has an average back pain intensity ≥ 5.0 cm on the 10.0 cm Visual Analog Scale (VAS)
at the time of enrollment with moderate to severe chronic leg pain
3. Be willing and capable of giving written informed consent to participate in this
clinical study based on voluntary agreement after a thorough explanation of the
subject's participation has been provided.
4. Be willing and capable of subjective evaluation, read and understand English-written
questionnaires, and read, understand and sign the written inform consent in English.
5. Be 18 years of age or older at the time of enrollment
6. Be on a stable pain medication regime, as determined by the study investigator, for at
least 30 days prior to enrolling in this study
7. Be willing to not increase pain medications from baseline through the 3-Month Visit
8. Be willing and able to comply with study-related requirements, procedures, and visits
Exclusion Criteria:
1. Has a medical, anatomical, and/or psychosocial condition that is contraindicated for
commercially available IntellisTM SCS systems as determined by the Investigator
2. Be concurrently participating in another clinical study
3. Has an existing active implanted device such as a pacemaker, another SCS unit,
peripheral nerve stimulator, and/or drug delivery pump, etc.
4. Has pain in other area(s) and/or medical condition requiring the regular use of
significant pain medications that could interfere with accurate pain reporting, study
procedures, and/or confound evaluation of study endpoints, as determined by the
Investigator
5. Has mechanical spine instability as determined by the Investigator
We found this trial at
1
site
Click here to add this to my saved trials